Medical/Pharmaceuticals
Akeso Announces Oral Presentation of Ivonescimab (PD-1/VEGF Bi-Specific) in First-line Treatment of ES-SCLC on ACLC 2022
HONG KONG, Oct. 30, 2022 /PRNewswire/ -- Akeso, Biopharma (9926. HK) ("Akeso") released the Phase Ib clinical results of Ivonescimab (PD-1/VEGF bi-specific, AK112) in combination with etoposide and carboplatin in first-line treatment of extensive-stage small-cell lung cancer(ES-SCLC), in an oral ...
2022-10-31 08:40
1736
GenesisCare and PreludeDx(TM) present compelling Australian-first DCISionRT Study Interim Analysis during Breast Cancer Awareness Month 45% change in treatment recommendations when using DCISionRT
CALIFORNIA CITY, Calif., Oct. 30, 2022 /PRNewswire/ -- GenesisCare, a leading provider of integrated cancer care globally, and Prelude Corporation (PreludeDx(TM)), a leader in molecular diagnostics and precision medicine, today announced interim results from the AUSPREDICT registry. Data presente...
2022-10-31 05:00
1646
Nuevocor to Present Pre-clinical Data on its Gene Therapy Candidate for LMNA Dilated Cardiomyopathy at American Heart Association Scientific Sessions 2022
SINGAPORE, Oct. 28, 2022 /PRNewswire/ -- Nuevocor, a pre-clinical stage cardiac gene therapy company, announced today that it will present new preclinical data on its adeno-associated virus (AAV) gene therapy forLMNA dilated cardiomyopathy at the American Heart Association (AHA) Scientific Sessio...
2022-10-28 22:30
2889
LISCure Biosciences Announces Oral Presentation of New Drug Candidate for NASH at Upcoming AASLD The Liver Meeting 2022
The efficacy and mechanism of NASH microbiome-based therapy for liver fibrosis, steatosis, and inflammation have been confirmed in various animal models SEOUL, South Korea, Oct. 28, 2022 /PRNewswire/ -- LISCure Biosciences, a clinical-stage biopharmaceutical company developing microbe-oriented ne...
2022-10-28 21:00
2069
Hinova Disclosed the Preclinical Results of HP518 (Oral AR PROTAC) at the 5th Annual TPD Summit
BOSTON, Oct. 28, 2022 /PRNewswire/ -- Hinova Pharmaceuticals Inc. (STAR: 688302), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cancers and metabolic diseases through targeted protein degradation technologies, today presented their preclinical results of ...
2022-10-28 20:30
2339
NDA for New Second-Line Indication of CAR T-Cell Therapy Product YIKAIDA (Axicabtagene Ciloleucel Injection) Approved for CDE Review
Fosun Kite to Participate in the Fifth CIIE to Showcase New Options in Cell Therapy SHANGHAI, Oct. 27, 2022 /PRNewswire/ -- October 24 brought good news from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) that the NDA for new second-line indication o...
2022-10-28 01:37
2275
WuXi Biologics Provides Corporate Updates
SHANGHAI, Oct. 27, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today updated its recent corporate progress. Recent Business Milestone Despite the global dynamic situation and funding challeng...
2022-10-27 22:13
2566
Simcere Receives FDA Clearance of Investigational New Drug Application (IND) for Bi-functional Fusion Protein, SIM0237
Second US IND approval this year for the global pharmaceutical group NANJING, China and BOSTON, Oct. 27, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK), an innovative global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the com...
2022-10-27 21:25
2194
Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US
SUZHOU, China, Oct. 27, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment and dosing of 120 subj...
2022-10-27 21:22
2182
Antengene to Host Research and Development Day on November 15th and 17th, 2022
* Virtual English Session: Tuesday, November 15 at 8:30 AM – 12:00 PM Eastern Time November 15 at 9:30 PM – November 16 at 1:00 AM Beijing Time * Hybrid Mandarin Session in Shanghai: Thursday, November 17 at 1:30 PM – 5:30 PM Beijing Time SHANGHAI and HONG KONG, Oct. 26, 2022 /PRNewswire/ -- An...
2022-10-27 11:07
3193
Cali Biosciences Announces Publications of Phase IIa Results of Long-Acting Ropivacaine (CPL-01)
CPL-01, for Non-Opioid Treatment of Post-Operative Pain, Garners Publication of Clinical Data in Abdominoplasty and Presentation of Preclinical Data in Bony and Soft-Tissue ModelsSupporting Pharmacokinetics and Safety SAN DIEGO, Oct. 26, 2022 /PRNewswire/ -- Cali Biosciences Co., Ltd. (hereinaft...
2022-10-27 10:07
1937
Samsung Biologics Reports Third Quarter 2022 Financial Results
* Recorded consolidated revenue of KRW 873 billion in Q3'22 * Recorded consolidated operating profit of KRW 324.7 billion in Q3'22 * Started partial operations at Plant 4 within 23 months since groundbreaking as previously committed and launched two new development platforms INCHEON, South K...
2022-10-27 07:35
2070
Lunit Joins World Economic Forum Global Innovators Community
* Lunit invited to join the World Economic Forum's Global Innovators Community, an invitation-only group of the world's most promising start-ups and scale-ups at the forefront of technological and business model innovation * In 2020, Lunit was nominated among hundreds of candidates as one of t...
2022-10-26 21:00
2553
Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting
MELBOURNE, Australia and SAN FRANCISCO , Oct. 26, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced a poster presentation f...
2022-10-26 19:25
2157
WuXi AppTec Reports Record Year-to-Date Results in 2022, Third Quarter Revenue over RMB10 Billion
Revenue Up 71.9% Year-Over-Year to RMB28,395 Million Net Profit Attributable to Owners of the Company Up 107.1% Year-Over-Year to RMB7,378 Million Diluted Earnings Per Share (EPS) Up 90.1% Year-Over-Year to RMB2.30 Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 77.9% Year...
2022-10-26 19:06
3418
Meet the female scientists who develop cellular and gene therapies
SHENZHEN, China, Oct. 26, 2022 /PRNewswire/ -- Inside Namtai Inno Park in Guangming District hides a low-profile biomedical development firm – Shenzhen Wingor Biotechnology Co. Upon entering the company, one may feel a different vibe – something gentle yet vibrant, maybe because it's female-domin...
2022-10-26 17:07
2109
Yiling Pharmaceutical Exhibiting its Innovative TCM Products during CHEXPO Macau 2022
SHIJIAZHUANG, China, Oct. 26, 2022 /PRNewswire/ -- CHEXPO Macau 2022 was officially opened onOctober 20, 2022. As one of the top 10 TCM enterprises in China, Yiling Pharmaceutical exhibited a number of its patented TCM and health products during the expo. As an international and frontier city of ...
2022-10-26 16:52
2029
ImmVira announced its signing of Series C+ financing and negotiation with further investors for the round
SHENZHEN, China, Oct. 26, 2022 /PRNewswire/ -- ImmVira announced its successful signing of Series-C+ financing transaction documents with the first batch of investors recently. This round of financing was initiated by China Merchants China Direct Investments Limited with participation of Lifebay ...
2022-10-26 14:26
2026
WuXi Biologics Announces GMP Release of 48,000L Commercial Drug Substance Manufacturing Facility in Hebei, China
- The 11th drug substance facility is released for cGMP operation in the WuXi Biologics' global manufacturing network. This new facility enhances the company's capability of providing commercial manufacturing at 4,000L to 20,000L scale, facilitating any project initiation within four weeks. - ...
2022-10-26 12:30
2118
Alwin Capital's New Dual-Currency Fund Closed and Exceeded Fundraising Target
BEIJING, Oct. 25, 2022 /PRNewswire/ -- Alwin Capital recently closed a new
dual-currency fund, raising overUS$300 million, which exceeds their fundraising
target.
2022-10-25 23:10
2106
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
8873
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7709